• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.630 +0.190 (+5.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,039,076
Open 3.410
Bid (Size) 3.640 (500)
Ask (Size) 3.650 (800)
Prev. Close 3.440
Today's Range 3.410 - 3.700
52wk Range 2.770 - 7.180
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Market Just Told You Which Layer Of AI Biology It Is Paying For
September 03, 2026
Issued on behalf of MindWalk Holdings Corp. 
From Market Updates
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates ↗
August 17, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and... 
Via MarketBeat
Topics Artificial Intelligence

Performance

YTD
-13.6%
-13.6%
1 Month
+10.3%
+10.3%
3 Month
+9.3%
+9.3%
6 Month
+3.4%
+3.4%
1 Year
-21.4%
-21.4%

More News

Read More
News headline image
Recursion (RXRX) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Recursion Pharmaceuticals Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 05, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
August 04, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
July 30, 2026
Via The Motley Fool
Topics Workforce
News headline image
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
July 29, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗
July 14, 2026
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
July 11, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
July 05, 2026
Via The Motley Fool
Topics ETFs
News headline image
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗
July 04, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗
July 03, 2026
Via The Motley Fool
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 30, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market ↗
June 27, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗
June 26, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 02, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conferences
June 02, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
May 29, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
May 25, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗
May 19, 2026
Via MarketBeat
Topics Artificial Intelligence Economy Regulatory Compliance
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
May 11, 2026
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
From BioMedWire
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.630
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 09/04/26 04:00 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 611.39M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 611M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap